Nephrologists should embrace the holistic CKM approach to chronic disease and be part of the ongoing metabolic revolution by thinking beyond T2DM and becoming familiar with the beneficial effects of GLP-1 RAs on CVD and CKD risk in patients with overweight/obesity independent of the presence of T2DM or CKD
Stopping treatment with weight loss medications is associated with gradual weight gain and a loss of earlier improvements in heart and metabolic health, according to new research published by The BMJ
Use smooth, high-thread-count sheets
Im a doctor and these health problems, obesity and diabetes complications, are what Ive been interested in for years, he concludes
The doses of sulfonylurea and/or insulin may need to be reduced
MedBound Hub GLP-1 Drugs: Fighting Diabetes and Weight Gain General Madhumathi.N.Lambi December 25, 2025, 1:49pm 1 GLP-1 Drugs: Fighting Diabetes and Weight In recent years, GLP-1 receptor agonists have transformed the treatment landscape for type 2 diabetes and obesity, blurring the line between metabolic disease management and weight-loss therapy
